Risk of lung disease in the PI*SS genotype of alpha-1 antitrypsin: an EARCO research project.
Alpha-1 antitrypsin
Lung disease
PI*SS
Registries
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
26 Jun 2024
26 Jun 2024
Historique:
received:
20
02
2024
accepted:
12
06
2024
medline:
27
6
2024
pubmed:
27
6
2024
entrez:
26
6
2024
Statut:
epublish
Résumé
The PI*S variant is one of the most prevalent mutations within alpha-1 antitrypsin deficiency (AATD). The risk of developing AATD-related lung disease in individuals with the PI*SS genotype is poorly defined despite its substantial prevalence. Our study aimed to characterize this genotype and its risk for lung disease and compare it with the PI*ZZ and PI*SZ genotypes using data from the European Alpha-1 antitrypsin Deficiency Research Collaboration international registry. Demographic, clinical, functional, and quality of life (QoL) parameters were assessed to compare the PI*SS characteristics with the PI*SZ and PI*ZZ controls. A propensity score with 1:3 nearest-neighbour matching was performed for the most important confounding variables. The study included 1007 individuals, with PI*SS (n = 56; 5.6%), PI*ZZ (n = 578; 57.4%) and PI*SZ (n = 373; 37.0%). The PI*SS population consisted of 58.9% men, with a mean age of 59.2 years and a mean FEV1(% predicted) of 83.4%. Compared to PI*ZZ individuals they had less frequent lung disease (71.4% vs. 82.2%, p = 0.037), COPD (41.4% vs. 60%, p = 0.002), and emphysema (23.2% vs. 51.9%, p < 0.001) and better preserved lung function, fewer exacerbations, lower level of dyspnoea, and better QoL. In contrast, no significant differences were found in the prevalence of lung diseases between PI*SS and PI*SZ, or lung function parameters, exacerbations, dyspnoea, or QoL. We found that, as expected, the risk of lung disease associated with the PI*SS genotype is significantly lower compared with PI*ZZ, but does not differ from that observed in PI*SZ individuals, despite having higher serum AAT levels. www. gov (ID: NCT04180319).
Sections du résumé
BACKGROUND
BACKGROUND
The PI*S variant is one of the most prevalent mutations within alpha-1 antitrypsin deficiency (AATD). The risk of developing AATD-related lung disease in individuals with the PI*SS genotype is poorly defined despite its substantial prevalence. Our study aimed to characterize this genotype and its risk for lung disease and compare it with the PI*ZZ and PI*SZ genotypes using data from the European Alpha-1 antitrypsin Deficiency Research Collaboration international registry.
METHOD
METHODS
Demographic, clinical, functional, and quality of life (QoL) parameters were assessed to compare the PI*SS characteristics with the PI*SZ and PI*ZZ controls. A propensity score with 1:3 nearest-neighbour matching was performed for the most important confounding variables.
RESULTS
RESULTS
The study included 1007 individuals, with PI*SS (n = 56; 5.6%), PI*ZZ (n = 578; 57.4%) and PI*SZ (n = 373; 37.0%). The PI*SS population consisted of 58.9% men, with a mean age of 59.2 years and a mean FEV1(% predicted) of 83.4%. Compared to PI*ZZ individuals they had less frequent lung disease (71.4% vs. 82.2%, p = 0.037), COPD (41.4% vs. 60%, p = 0.002), and emphysema (23.2% vs. 51.9%, p < 0.001) and better preserved lung function, fewer exacerbations, lower level of dyspnoea, and better QoL. In contrast, no significant differences were found in the prevalence of lung diseases between PI*SS and PI*SZ, or lung function parameters, exacerbations, dyspnoea, or QoL.
CONCLUSIONS
CONCLUSIONS
We found that, as expected, the risk of lung disease associated with the PI*SS genotype is significantly lower compared with PI*ZZ, but does not differ from that observed in PI*SZ individuals, despite having higher serum AAT levels.
TRIAL REGISTRATION
BACKGROUND
www.
CLINICALTRIALS
RESULTS
gov (ID: NCT04180319).
Identifiants
pubmed: 38926693
doi: 10.1186/s12931-024-02879-y
pii: 10.1186/s12931-024-02879-y
doi:
Substances chimiques
alpha 1-Antitrypsin
0
SERPINA1 protein, human
0
Banques de données
ClinicalTrials.gov
['NCT04180319']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
260Informations de copyright
© 2024. The Author(s).
Références
Strnad P, McElvaney NG, Lomas DA. Alpha1-Antitrypsin Deficiency. N Engl J Med. Apr 2020;9(15):1443–55.
doi: 10.1056/NEJMra1910234
Blanco I, de Serres FJ, Fernandez-Bustillo E, Lara B, Miravitlles M. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J. 2006;27:77–84.
doi: 10.1183/09031936.06.00062305
pubmed: 16387939
Elliott PR, Stein PE, Bilton D, Carrell RW, Lomas DA. Structural explanation for the deficiency of S alpha 1-antitrypsin. Nat Struct Biol. 1996;3:910–1.
doi: 10.1038/nsb1196-910
pubmed: 8901864
Seixas S, Marques PI. Known mutations at the cause of alpha 1-antitrypsin deficiency an updated overview of SERPINA I variation spectrum. Appl Clin Genet. 2021;14:173–94.
doi: 10.2147/TACG.S257511
pubmed: 33790624
pmcid: 7997584
Ferrarotti I, Thun GA, Zorzetto M, Ottaviani S, Imboden M, Schindler C, et al. Serum levels and genotype distribution of alpha1-antitrypsin in the general population. Thorax. 2012;67:669–74.
doi: 10.1136/thoraxjnl-2011-201321
pubmed: 22426792
Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, et al. European respiratory Society Statement: diagnosis and treatment of pulmonary disease in alpha-1 antitrypsin deficiency. Eur Respir J. 2017;50:1700610.
doi: 10.1183/13993003.00610-2017
pubmed: 29191952
Dahl M, Hersh CP, Ly NP, Berkey CS, Silverman EK, Nordestgaard BG. The protease inhibitor PI*S allele and COPD: a meta-analysis. Eur Respir J. 2005;26:67–76.
doi: 10.1183/09031936.05.00135704
pubmed: 15994391
McElvaney GN, Sandhaus RA, Miravitlles M, Turino GM, Seersholm N, Wencker M, et al. Clinical considerations in individuals with Alpha-1 antitrypsin PI*SZ genotype. Eur Respir J. 2020;55:pii1902410.
doi: 10.1183/13993003.02410-2019
Nuñez A, Belmonte I, Miranda E, Barrecheguren M, Farago G, Loeb E, et al. Association between circulating alpha-1 antitrypsin polymers and lung and liver disease. Respir Res. 2021;22:244.
doi: 10.1186/s12931-021-01842-5
pubmed: 34526035
pmcid: 8442448
De Serres F, Blanco I. Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis. 2012;6(5):277–95.
doi: 10.1177/1753465812457113
pubmed: 22933512
Miravitlles M, Herepath M, Priyendu A, Sharma S, Vilchez T, Vit O, et al. Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews. Eur Respir Rev. 2022;31(163):210262.
doi: 10.1183/16000617.0262-2021
pubmed: 35321931
pmcid: 9488933
Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, et al. Protocol for the EARCO Registry: a pan-european observational study in patients with α
doi: 10.1183/23120541.00181-2019
pubmed: 32154291
pmcid: 7049712
Miravitlles M, Turner AM, Torres-Duran M, Tanash H, Rodríguez-García C, López-Campos JL, et al. Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry. Respir Res. 2022;23(1):352.
doi: 10.1186/s12931-022-02275-4
pubmed: 36527073
pmcid: 9756677
Miravitlles M, Turner AM, Torres-Duran M, Tanash H, Rodríguez-García C, López-Campos JL, et al. Characteristics of individuals with alpha-1 antitrypsin deficiency from Northern and Southern European countries: EARCO international registry. Eur Respir J. 2023;61(3):2201949.
doi: 10.1183/13993003.01949-2022
pubmed: 36997232
Jones PW, Harding G, Berry P, Wilkund I, Chen WH, Kline-Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648–54.
doi: 10.1183/09031936.00102509
pubmed: 19720809
EuroQoL Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
doi: 10.1016/0168-8510(90)90421-9
Greenwood JL, Joy EA, Stanford JB. The physical activity vital sign: a primary care tool to guide counseling for obesity. J Phys Act Health. 2010;7(5):571–6.
doi: 10.1123/jpah.7.5.571
pubmed: 20864751
Ramon MA, Esquinas C, Barrecheguren M, Pleguezuelos E, Molina J, Quintano JA, et al. Self-reported daily walking time in COPD: relationship with relevant clinical and functional characteristics. Int J Chron Obstruct Pulmon Dis. 2017;12:1173–81.
doi: 10.2147/COPD.S128234
pubmed: 28458527
pmcid: 5402919
Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, Tordera MP, Sánchez PR. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009;103(5):692–9.
doi: 10.1016/j.rmed.2008.12.005
pubmed: 19131231
Ogushi F, Hubbard RC, Fells GA, Casolaro MA, Curiel DT, Brantly ML, et al. Evaluation of the S-type of Alpha-1 antitrypsin as an in vivo and in vitro inhibitor of neutrophil elastase. Am Rev Respir Dis. 1988;137:364–70.
doi: 10.1164/ajrccm/137.2.364
pubmed: 3257660
Tan L, Dickens JA, Demeo DL, Miranda E, Perez J, Rashid ST, et al. Circulating polymers in α1-antitrypsin deficiency. Eur Respir J. 2014;43:1501–4.
doi: 10.1183/09031936.00111213
pubmed: 24603821
Miravitlles M, Anzueto A, Barrecheguren M. Nine controversial questions about augmentation therapy for alpha-1 antitrypsin deficiency: a viewpoint. Eur Respir Rev. 2023;32(170):230170.
doi: 10.1183/16000617.0170-2023
pubmed: 38056890
pmcid: 10698548
Tonelli AR, Brantly ML. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies. Ther Adv Respir Dis. 2010;4:289–312.
doi: 10.1177/1753465810373911
pubmed: 20650978
Attaway A, Majumdar U, Sandhaus RA, Nowacki AS, Stoller JK. An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis. 2019;14:2089–101.
doi: 10.2147/COPD.S208591
pubmed: 31564856
pmcid: 6734458
Torres-Durán M, López-Campos JL, Rodríguez-Hermosa JL, Esquinas C, Martínez-González C, Hernández-Pérez JM, et al. Demographic and clinical characteristics of patients with α
doi: 10.1183/23120541.00213-2022
pubmed: 36171983
pmcid: 9511153
Martín-González E, Hernández-Pérez JM, Pérez JAP, Pérez JAP, Pérez-García J, Herrera-Luis E et al. Alpha-1 antitrypsin deficiency and PI*S and PI*Z SERPINA1 variants are associated with asthma exacerbations. Pulmonology 2023:S2531-0437(23)00091 – 0.
Hernández-Pérez JM, Martín-González E, González-Carracedo MA. Alpha-1 Antitrypsin Deficiency and SERPINA1 variants could play a role in Asthma exacerbations. Arch Bronconeumol. 2023;59(7):416–7.
doi: 10.1016/j.arbres.2023.02.016
pubmed: 36948995